Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma

Peilin Cong, Tingmei Wu, Xinwei Huang, Huazheng Liang, Xiaofei Gao, Tian Li, Wanrong Li, Aiwen Chen, Hanxi Wan, Mengfan He, Danqing Dai, Zhen Li, Lize XiongFrontiers in Cell and Developmental Biology 2021 · DOI

TL;DR

This study identifies key m6A RNA methylation regulators and their target genes involved in glioma development and progression. They've developed a novel seven-gene signature that accurately predicts patient survival and shows potential for guiding personalized cancer therapies and drug development.

What Problem Does This Paper Address?

Glioma, a type of brain cancer, remains a significant challenge due to its aggressive nature and poor prognosis, even with current treatments like surgery, radiation, and chemotherapy. While the role of m6A RNA methylation in cancer is increasingly recognized, a comprehensive understanding of its regulators and their specific target genes in glioma, and their clinical prognostic value, is still needed. This paper aims to fill this gap by systematically investigating these m6A regulators and their targets to identify potential biomarkers for diagnosis and therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized large-scale public datasets (TCGA, CGGA, GEO, CPTAC) to analyze gene and protein expression profiles. Differential expression analysis was performed to identify genes that are significantly up- or down-regulated in glioma compared to normal tissues. Correlation analyses were used to understand the relationships between m6A regulators and their targets.
  • Prognostic Signature Development: Univariate and Lasso Cox regression analyses were used to identify genes that are significantly associated with patient overall survival. A prognostic gene signature was then constructed based on these identified genes.
  • Validation: Kaplan-Meier curves, multivariate Cox regression, and time-dependent ROC curves were used to validate the prognostic capacity of the developed gene signature.
  • Functional Studies: Cell culture experiments, including siRNA-mediated knockdown of key regulators (like METTL3), were conducted to investigate the molecular mechanisms underlying their role in glioma progression. Western blotting and qRT-PCR were used to assess gene and protein expression changes. Cell Counting Kit-8 (CCK-8) assays were performed to evaluate the impact on cell proliferation.
  • Drug Sensitivity Analysis: Data from the CellMiner database was used to explore the correlation between the expression of identified genes and their susceptibility to various anticancer drugs.

Datasets

The study utilized several large public datasets:

  • The Cancer Genome Atlas (TCGA): mRNA-seq and mRNA-array data for glioma, GBM, and LGG.
  • Chinese Glioma Genome Atlas (CGGA): mRNA-seq and mRNA-array data for glioma, GBM, and LGG.
  • Gene Expression Omnibus (GEO): mRNA-array data from datasets GSE108474 and GSE16011.
  • Clinical Proteome Tumor Analysis Consortium (CPTAC): Proteomic data for GBM.
  • Gene Expression Profiling Interactive Analysis 2 (GEPIA 2): Used for differential expression analysis.
  • m6A2Target database: To identify validated and potential m6A targets.
  • CellMiner database: For RNA-seq and compound activity data (NCI-60 cell line set).

Key Insights and Ideas

  • m6A Regulators are Key Players in Glioma: The study strongly implicates several m6A RNA methylation regulators (IGF2BP2, KIAA1429, METTL16, METTL3, and YTHDF1) and a substantial number of their target genes in the development and progression of glioma.
  • METTL3 and the Notch Pathway: A significant finding is the demonstration that METTL3 activates the Notch signaling pathway by regulating its direct targets (NOTCH3, DLL3, and HES1). This pathway is crucial for glioma tumorigenesis and presents a potential therapeutic avenue.
  • A Prognostic Signature for Glioma: The development and validation of a seven-gene signature (METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA) offer a promising tool for predicting glioma patient survival.
  • Drug Response Correlations: The identified genes are linked to the response of cancer cell lines to 81 different anticancer drugs, suggesting their potential utility in guiding therapeutic choices and in the development of new drugs.

Key Results

  • Differential Expression: Several m6A regulators and their targets were found to be consistently up- or down-regulated in glioma, GBM, and LGG tissues compared to normal tissues.
  • Survival Association: 181 genes were identified as consistently associated with overall survival in glioma patients. Of these, 154 genes with high expression correlated with better survival, while 27 genes with high expression correlated with poorer survival.
  • Seven-Gene Signature: A prognostic gene signature comprising METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA was established and validated. This signature demonstrated a good capability in predicting glioma survival across multiple datasets, with high-risk patients showing significantly shorter overall survival.
  • Independent Prognostic Factors: Multivariate Cox regression analysis identified the seven-gene signature, age, recurrent/secondary status, high WHO grade, and 1p19q non-codeletion as independent prognostic factors for glioma.
  • Drug Susceptibility: The study found correlations between the expression of key regulators and targets and the susceptibility to 81 anticancer drugs. For instance, NASP expression showed a positive relevance with 21 anticancer drug responses.

Limitations and Future Work

  • Limitations: While the study uses multiple large datasets for robust analysis, the authors acknowledge that the findings are primarily based on retrospective data. The precise mechanisms by which all identified targets contribute to glioma progression require further in-depth investigation.
  • Future Work: The authors suggest that the identified seven-gene signature could guide therapeutic customization and clinical decision-making. The link between these genes and drug responses opens avenues for early-phase clinical trials and the development of novel anticancer drugs targeting these pathways. Further validation of the prognostic signature in prospective clinical trials would be beneficial.

Summary updated

Abstract

m6A RNA methylation regulators can regulate the growth, progression, and invasion of glioma cells by regulating their target genes, which provides a reliable support for the m6A regulator-target axes as the novel therapeutic targets and clinical prognostic signature in glioma. This study aimed to explore the role and prognostic value of m6A RNA methylation regulators and their targets. Expression profiles and clinicopathological data were obtained from the Chinese Glioma Genome Atlas (CGGA), The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Clinical Proteome Tumor Analysis Consortium (CPTAC) datasets. Differential expression and correlation analyses were performed between normal and glioma tissues at mRNA and protein levels. Univariate Cox regression, survival, and Lasso Cox regression analyses were conducted to identify and establish the prognostic gene signature. Kaplan-Meier curve, multivariate Cox regression analysis, and ROC were utilized to evaluate the prognostic capacity of the prognostic gene signature. The correlation analysis, systematic bioinformatics analysis, and cell experiment were performed to further understand the potential underlying molecular mechanisms and drug sensitivity. Our results suggested that IGF2BP2, KIAA1429, METTL16, and METTL3, as well as 208 targets are involved in the occurrence of glioma, GBM, and LGG. YTHDF1 and 78 targets involved the occurrence of glioma and GBM, not LGG, among which 181 genes were associated with overall survival. From other findings and our cell experiment results, we demonstrated that METTL3 can activate Notch pathway and facilitate glioma occurrence through regulating its direct targets NOTCH3, DLL3, and HES1, and Notch pathway genes may serve as the potential treatment targets for glioma. Our study established and validated a seven-gene signature comprising METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA, with a good capability for predicting glioma survival, which may guide therapeutic customization and clinical decision-making. These genes were identified to influence 81 anticancer drug responses, which further contributes to the early phase clinical trials of drug development.
BibTeX
@inproceedings{cong2021identification,
  author = {Peilin Cong and Tingmei Wu and Xinwei Huang and Huazheng Liang and Xiaofei Gao and Tian Li and Wanrong Li and Aiwen Chen and Hanxi Wan and Mengfan He and Danqing Dai and Zhen Li and Lize Xiong},
  title = {{Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.709022},
}
Figure